Clinical Trials Using FLT3 Inhibitor FF-10101 Succinate

Clinical trials are research studies that involve people. The clinical trials on this list are studying FLT3 Inhibitor FF-10101 Succinate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

    A Phase 1 / 2a dose escalation and dose ranging study of FF-10101-01 in subjects with relapsed or refractory acute myeloid leukemia to determine the safety, tolerability, PK and preliminary efficacy. A total of 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD). Phase 2a will consist of up to 3 dose levels (high, medium, and low) of which subjects with FLT3 mutations will randomly be assigned.
    Location: 7 locations